Cargando…
Studying TIGIT activity against tumors through the generation of knockout mice
The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of addit...
Autores principales: | Rishiq, Ahmed, Bsoul, Reem, Pick, Ophir, Mandelboim, Ofer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228407/ https://www.ncbi.nlm.nih.gov/pubmed/37261087 http://dx.doi.org/10.1080/2162402X.2023.2217735 |
Ejemplares similares
-
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020) -
Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021) -
TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020) -
Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT
por: Charpak-Amikam, Yoav, et al.
Publicado: (2022) -
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)